IP Library › Granted Patent US 7,557,198
Granted Patent B2
US 7,557,198 · App. 11/417,450 · Granted Jul 7, 2009

Acute myelogenous leukemia biomarkers

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,557,198
App. No.
11/417,450
Granted
Jul 7, 2009
Kind
B2
Abstract

The present invention provides novel compositions and their use in classifying acute myelogenous leukemia.

Claims (10)

1. An AML biomarker consisting of between 3 and 65 different probe sets, wherein at least 20% of the different probe sets consist of one or more isolated polynucleotides of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13; wherein a first probe set consists of one or more isolated polynucleotides of 1000 or more contiguous nucleotides of SEQ ID NO:6 or 1000 or more contiguous nucleotides fully complementary to SEQ ID NO:6; wherein a second probe set consists of one or more isolated polynucleotides of 1000 or more contiguous nucleotides of SEQ ID NO:12 or 1000 or more contiguous nucleotides fully complementary to SEQ ID NO:12; and wherein a third probe set consists of one or more isolated polynucleotides of 1000 or more contiguous nucleotides of SEQ ID NO:13 or 1000 or more contiguous nucleotides fully complementary to SEQ ID NO:13.

2. The AML biomarker of claim 1 wherein at least 50% of the different probe sets consist of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13.

3. The AML biomarker of claim 1 wherein at least 70% of the different probe sets consist of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13.

4. The AML biomarker of claim 1 wherein at least 80% of the different probe sets consist of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13.

5. The AML biomarker of claim 1 wherein at least 90% of the different probe sets consist of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13.

6. The AML biomarker of claim 1 wherein the one or more isolated polynucleotides of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13 are detectably labeled.

7. The AML biomarker of claim 6 wherein the detectable label is a fluorescent dye.

8. The AML biomarker of claim 1 , wherein the one or more isolated polynucleotides of 20 or more contiguous nucleotides of one of SEQ ID NOS:1-13 or 20 or more contiguous nucleotides fully complementary to one of SEQ ID NOS:1-13 comprise DNA.

9. The AML biomarker of claim 8 , wherein the DNA is single stranded DNA.

10. The AML biomarker of claim 8 , wherein the DNA is double stranded DNA.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Sep 4, 2025
From: NEW MEXICO MEZZANINE PARTERSN, L.P.; NEW MEXICO CO-INVESTMENT FUND, L.P.
To: EXAGEN INC.
Reel/Frame 072159/0497 →
SECURITY INTEREST Recorded Apr 25, 2025
From: EXAGEN INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070952/0802 →
RELEASE OF SECURITY INTEREST Recorded Sep 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043784/0828 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Oct 15, 2013
From: EXAGEN DIAGNOSTICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031414/0660 →
SECURITY AGREEMENT Recorded Nov 4, 2010
From: EXAGEN DIAGNOSTICS, INC.
To: NEW MEXICO MEZZANINE PARTNERS, L.P.; NEW MEXICO CO-INVESTMENT FUND, L.P.
Reel/Frame 025317/0170 →
SECURITY AGREEMENT Recorded Sep 23, 2010
From: EXAGEN DIAGNOSTICS, INC.
To: LOS ALAMOS NATIONAL BANK
Reel/Frame 025227/0471 →
SECURITY AGREEMENT Recorded Apr 17, 2008
From: EXAGEN DIAGNOSTICS, INC.
To: TULLIS-DICKERSON CAPITAL FOCUS III, L.P.
Reel/Frame 020819/0481 →
SECURITY AGREEMENT Recorded Nov 14, 2007
From: EXAGEN DIAGNOSTICS, INC.
To: TULLIS-DICKERSON CAPITAL FOCUS III, L.P.
Reel/Frame 020111/0927 →
SECURITY AGREEMENT Recorded Feb 2, 2007
From: EXAGEN DIAGNOSTICS, INC.
To: TULLIS-DICKERSON CAPITAL FOCUS III, L.P.
Reel/Frame 018849/0316 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2006
From: DAVIS, LISA; HARRIS, COLE
To: EXAGEN DIAGNOSTICS, INC. A CORPORATION OF THE STATE OF DELAWARE
Reel/Frame 018112/0443 →